XTX Topco’s Aspire Biopharma ASBP Stock Holding History

XTX Topco’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-221	Closed	-$35K	–	4554
2025 Q4	$35K	Buy	221 +198	+861%	+$49.5K	﹤0.01%	2919
2025 Q3	$5.74K	Buy	+23	New	+$11.5K	﹤0.01%	2465

Other funds holding ASBP

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

XTX Topco's ASBP Position: Q1 2026 in Review

XTX Topco sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 221 shares — an estimated $35K sold.

XTX Topco first reported a position in ASBP in Q3 2025 and held it in 2 quarters. The position peaked at $35K in Q4 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

XTX Topco reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 221 Aspire Biopharma shares in Q1 2026, an estimated $35K.
XTX Topco first reported a position in Aspire Biopharma in Q3 2025 and held it in 2 quarters.
XTX Topco's Aspire Biopharma position peaked at $35K in Q4 2025.
12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.